Erythritol Study Raises Alarm Over Brain Vascular Health

A single sweetener may sabotage brain vessels

The University of Colorado Boulder team showed that erythritol, the sugar‑free sweetener found in many diet drinks, spikes oxidative stress in brain blood‑vessel cells. The researchers exposed human cerebral vascular cells to a solution containing roughly the amount of erythritol in one typical soda can – about 30 grams – for three hours. After exposure the cells produced nearly twice the reactive oxygen species of untreated cells and secreted far less nitric oxide, a molecule that keeps vessels relaxed.

Auburn Berry, the study’s first author, explained that the compound interferes with a key activation step in the cells, bluntly reducing nitric oxide output. Thomas M. Holland, a physician‑scientist not involved in the work, warned that the loss of nitric oxide can impair circulation and potentially trigger neurovascular damage. The findings, presented at the 2025 American Physiology Summit and published in the Journal of Applied Physiology, add a mechanistic layer to epidemiological signals that link high blood erythritol levels with heart attacks and strokes.

Why oxidative stress matters

Oxidative stress describes an imbalance where free radicals outpace antioxidant defenses. In the study, the erythritol‑treated cells doubled their reactive oxygen species and simultaneously boosted two antioxidant enzymes, a classic stress response. The surge in free radicals can damage cellular membranes, proteins, and DNA, compromising the integrity of the blood‑brain barrier.

Nitric oxide, by contrast, is a vasodilator. When its production drops, vessels constrict, blood flow slows, and the risk of clot formation rises. Holland noted that reduced nitric oxide “could also add to the risk of ischemic stroke,” echoing the earlier epidemiological work that flagged erythritol as a possible stroke risk factor. The cell model does not prove that drinking a diet soda will cause a stroke, but it shows a direct biochemical pathway that could translate into vascular dysfunction if the exposure is chronic.

The broader sugar‑substitute debate

Erythritol entered the U.S. food additive list in 2001 and has been marketed as a zero‑calorie alternative for weight loss and blood‑sugar management. Its popularity surged with the keto diet, leading to its inclusion in snack bars, energy drinks, and chewing gum. The new data challenge the assumption that “non‑caloric equals non‑harmful.”

Consumers have long trusted the label “approved food additive” as a safety blanket. Yet the study highlights how a compound can pass regulatory scrutiny while still harboring subtle cellular effects. The research community now faces pressure to reassess acceptable daily intake levels and to communicate nuanced risk without triggering panic. As the study authors caution, the exposure in the lab mirrors a single beverage serving; real‑world consumption patterns vary widely.

Fighting health misinformation with evidence

The erythritol controversy will likely ignite a wave of online claims, some exaggerating the danger, others dismissing it outright. Health professionals have spent decades battling misinformation, a struggle exemplified by Hilda Bastian’s journey from home‑birth advocate to evidence‑based medicine champion. Bastian’s experience shows that credibility, not rhetoric, shifts public opinion. She learned that shouting at skeptics deepens resistance, while transparent, data‑driven dialogue builds trust.

Applying Bastian’s lessons, scientists and journalists should present the erythritol findings with clear caveats: the study used isolated cells, not whole humans; the exposure mimicked a single drink, not chronic intake; and the broader epidemiological link remains correlational. Overstating the risk fuels alarmism; understating it invites complacency. A balanced approach equips readers to weigh the evidence against personal dietary choices.

Testing, surveillance, and public‑health response

The erythritol story underscores the value of rigorous testing, a principle echoed in unrelated public‑health successes. Recent reports from an unnamed health agency showed that suspected Ebola cases dropped from 1,100 to 437 as testing capacity expanded. The steep decline illustrates how scaling diagnostics can clarify outbreak realities and direct resources efficiently.

Both cases reveal a common thread: data quality shapes policy. Whether measuring viral prevalence or cellular oxidative stress, robust testing uncovers hidden patterns that inform interventions. Health authorities should invest in laboratory infrastructure not only for emerging pathogens but also for monitoring the biochemical impacts of everyday consumables.

What to watch next

Track the upcoming FDA review of erythritol’s acceptable daily intake, slated for the next quarter. Also monitor longitudinal studies that assess cardiovascular outcomes in populations with high erythritol consumption. Finally, watch how media outlets frame the findings; credible reporting will hinge on quoting the original cell data and contextualizing it within the broader evidence base.